Bristol-Myers Squibb
Discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 9 % | - | (2 %) | 7 % | (4 %) | (7 %) | (1 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 44 % | 43 % | 43 % | 33 % | 38 % | 38 % | 37 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 15 % | 14 % | 18 % | (19 %) | 19 % | 22 % | 23 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 22 % | 21 % | 21 % | 23 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Bristol Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company operates primarily in the healthcare and pharmaceutical markets, focusing on areas such as oncology (cancer treatment), immunology (autoimmune diseases), and cardiovascular diseases.
BMS serves a diverse range of clients, including hospitals, healthcare providers, and patients. The company’s business model revolves around extensive research and development (R&D) to create new drugs and therapies. This involves significant investment in scientific research to explore potential treatments and bring them to market. BMS makes money by selling these innovative medicines and therapies once they receive regulatory approval.
The company is also involved in the production of generic drugs, which are more affordable versions of previously approved innovative medicines. These generics contain the same active ingredients and meet stringent quality and safety standards. By offering both innovative and generic medicines, BMS aims to increase the availability of affordable healthcare solutions.
BMS places a strong emphasis on sustainability and corporate responsibility. The company is committed to achieving Environmental, Social, and Governance (ESG) goals, which include building trust with stakeholders and making a positive impact on patients and the world. BMS also supports the establishment of regulatory pathways for biosimilars, which are highly similar to already approved biological medicines, ensuring they meet efficacy and safety standards.
In summary, Bristol Myers Squibb is a leading biopharmaceutical company focused on developing and delivering innovative and affordable medicines to improve patient outcomes. The company’s commitment to research, sustainability, and regulatory compliance positions it as a key player in the global healthcare market.
Keywords: biopharmaceutical, oncology, immunology, cardiovascular, research, development, generics, biosimilars, sustainability, healthcare.
Tech stack
